VANCOUVER, British Columbia — Researchers found no significant differences in IOP elevations in patients treated with three different anti-VEGF agents, according to a poster presented here at the Association for Research in Vision and Ophthalmology meeting.
David Na, BS, and colleagues from the University of Maryland School of Medicine, Baltimore, evaluated 73 patients who initially received treatment with a single anti-VEGF agent.
“Between the three agents (bevacizumab, aflibercept, ranibizumab), we didn’t find any significant differences in IOP,” Na told
Uncategorized